This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
adalimumab
Adalimumab
Fully human anti-TNFα monoclonal antibody (IgG1); neutralizes soluble and membrane-bound TNFα → ↓ NF-κB/MAPK inflammation. FDA-approved for RA, psoriasis, IBD, AS, JIA and 10 other indications. Humira was the world's best-selling drug 2012–2022.
Entry Metadata
| Field | Value |
|---|---|
| ID | adalimumab |
| Name | Adalimumab |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Stream | 01-modern |
Cross-Atlas Connections
Sources
- Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum. 2003;48(1):35-45. · PubMed 12528101
- Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65. · PubMed 17241859
- Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum. 2004;50(5):1400-11. · PubMed 15146409
- Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-79. · PubMed 18155297